Will Ozempic take some weight off the ResMed share price?
Sleep apnoea is a widespread and serious condition, affecting many areas of our health — and ResMed’s (ASX:RMD) CPAP machines have been at the forefront of treatment.
But will Ozempic’s (and other brands’) weight loss drugs put a dent in ResMed’s market?
Our Chief Investment Officer, Scott Phillips, sits down with Motley Fool analyst Mitchell Lawler to chat about the company, and the opportunities (and risks) of an investment… plus whether he thinks it could be a market-beater.
As always, any advice we give in these videos is general in nature and doesn’t take your personal needs, objectives, goals or risk tolerance into account. You should decide for yourself (or speak to a licenced personal financial adviser to help you decide) whether it’s right for you.
